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he history of cancer immunotherapy dates
back to 1890 when Coley first demonstrated
that bacterial products, he coined “Coley
toxins,” could induce regression of established inoper-
able tumors. When Coley’s work was finally published
in 1953,1 it sparked the beginning of cancer immu-
notherapy and led to the application of Bacillus
Calmette-Guerin (BCG) for the treatment of solid
tumors, such as bladder cancer, in the 1960s. Hence-
forth, research scientists have been striving to devise
ways to reproducibly stimulate an effective anti-tumor
immune response for the treatment of cancer. The
next major milestones in immunotherapy came in the
1970s and 1980s with the discovery of cytokines such
as interferon alpha (IFN-α) and interleukin-2 (IL-2),
identification of the first tumor-associated antigens
(TAAs), development of tumor-specific monoclonal
antibodies (mAbs), and the first successful application
of adoptive cell therapy (ACT) to treat cancer.2
Clinical studies demonstrated that stimulating the
antitumor immune response with immunomodulatory
cytokines such as IFN-α or IL-2 could mediate regres-
sion of established tumors.3,4 These data ultimately led
to regulatory approval of IFN-α2 for hairy cell leukemia
in 1986 and recombinant IL-2 (rIL-2) for the treatment
of metastatic renal cell carcinoma in 1992 and meta-
static melanoma in 1998. Among patients with
advanced metastatic melanoma treated with high-
dose rIL-2, 5%– 10% experienced durable complete
responses and many remained disease-free more than
20 years later.5 However, treatment with high-dose rIL-
2 did not improve overall survival and presents many
challenges, including severe toxicity. Unfortunately, to
this day, it remains unclear why a small percentage of
patients benefit while the vast majority do not. No
biomarker of response has ever been identified.
During this time, landmark research was being
conducted at the National Cancer Institute to isolate
and characterize tumor-infiltrating lymphocytes
(TILs), which could now be grown ex vivo with
IL-2. The culmination of this research led to the0093-7754 & 2014 Elsevier Inc.
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Open access under CC BY-NC-ND license.successful identification of TAAs and tumor-specific
antigens (TSAs) and to the first demonstration in
1985 that ACT using tumor-specific TILs could
induce tumor regression in patients with advanced
cancer.4 The characterization of TAAs and TSAs
spurred the development of therapeutic cancer
vaccines using peptides, whole proteins, dendritic
cells (DCs), recombinant viruses, whole cells, and
plasmid DNA. However, with few exceptions these
vaccine strategies have failed. The greatest challenge
facing vaccines and immunotherapy in general has
been the immunosuppressive tumor microenviron-
ment. This hurdle can be overcome to some extent
by adoptive transfer of tumor-specific TILs, which
can be expanded ex vivo and reinfused in large
numbers (up to 1011 cells). When preceded by
lymphodepletion with chemotherapy or radiation
to eliminate regulatory T cells and myeloid-derived
suppressor cells, ACT has been shown to mediate
reproducible and durable complete tumor regression
in up to 20% of heavily pretreated patients with
melanoma.6–9 Although traditional patient-specific
ACT is cumbersome and costly, efforts to make this
approach more widely applicable are ongoing.
Tremendous progress has been made in the past
two decades with regard to understanding the com-
plex interactions between tumors and the immune
system and developing innovative ways to manipu-
late the antitumor immune response.10 As a result,
immunotherapy has achieved an important mile-
stone in recent years, improving overall survival in
patients with advanced metastatic disease (specifi-
cally melanoma and prostate cancer). In part, this
achievement comes from understanding how tumor
cells exploit immune checkpoint receptors, such as
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-
4) or programmed cell death 1 (PD-1) expressed on
activated T cells, to suppress the anti-tumor immune
response. Antibodies against CTLA-4 and PD-1 can
release the brakes on the immune response and
allow T cells to expand, produce cytokines, and
carry out their normal effector functions. However,
this also can lead to autoimmune reactions that
range from bothersome to life-threatening. This
achievement also comes from designing better DC-
based vaccines that take advantage of decades of
research to understand how to supercharge DCs to
elicit an effective and sustained anti-tumor immune
response. The recent success in melanoma andS1-S2 S1
Jeffrey S. WeberS2prostate cancer has reignited the hope that immu-
notherapy could be an effective strategy for a wide
range of solid tumors. The growth of clinical
research in this area has been impressive, and every-
one is working to take advantage of our improved
understanding of tumor immunology to overcome
the challenges that have limited the potential of
cancer immunotherapy in the past.
In this supplement, Mary (Nora) Disis, MD
(Tumor Vaccine Group, University of Washington,
Seattle, WA), first discusses the mechanism of action
of the various approaches to immunotherapy. There-
after, Jeffrey Weber, MD, PhD (H. Lee Moffitt Cancer
Center and Research Institute, Tampa, FL), provides
a clinical perspective on where we are today
in the development of cancer immunotherapy
with a focus on immune checkpoint inhibitors
and therapeutic vaccines. Finally, Brian Rini, MD
(Cleveland Clinic, Cleveland, OH), discusses future
approaches in cancer immunotherapy with a focus
on combination strategies.
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